Scarica l'app Stockscreener
0.5562
4.65%
-0.0271
Dopo l'orario di chiusura:
.56
0.0038
+0.68%
Precedente Chiudi:
$0.5833
Aprire:
$0.59
Volume 24 ore:
285.24K
Relative Volume:
0.64
Capitalizzazione di mercato:
$48.58M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-2.1028
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-0.86%
1M Prestazione:
-12.37%
6M Prestazione:
-54.41%
1 anno Prestazione:
-48.50%
Intervallo 1D:
$0.5451
$0.59
Intervallo di 1 settimana:
$0.54
$0.61
Portata 52W:
$0.4679
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.5562 | 48.58M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
(ONC) Stock Trading Blueprint (ONC:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics to Present New Pancreatic Cancer Data at Oncology Meeting Next Month - marketscreener.com
Oncolytics Biotech to Present Promising Pancreatic Cancer Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action - Barchart.com
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action | ONCY Stock News - GuruFocus
Breakthrough Pancreatic Cancer Treatment Data: How Pelareorep Activates Immune System to Fight Tumors - Stock Titan
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and biotech shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Developm - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Small-cap cancer therapy innovator raises $20M in flexible funding | 2025-04-11 | Investing News - Stockhouse
Oncolytics secures $20 million to advance cancer therapy development - The Pharma Letter
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. - GuruFocus
Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development - TipRanks
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital - Barchart.com
Oncolytics Biotech® Inc. - MENAFN.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Stocks In Play: Oncolytics Biotech® Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech’s Pelareorep Gains Attention at Key Oncology Event - TipRanks
Indo-Asian News Service - Indo-Asian News Service (IANS)
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
(ONC) Optimized Trading Opportunities (ONC:CA) - news.stocktradersdaily.com
What Nvidia Stock Investors Should Know About Recent Tariff Updates - The Globe and Mail
Mideast stock markets tumble as US tariffs and low oil prices squeeze energy-producing nations - The Globe and Mail
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer - ACCESS Newswire
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - Quantisnow
Virtu Financial LLC Invests $90,000 in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing - MSN
What is Leede Financial’s Estimate for ONCY FY2025 Earnings? - The AM Reporter
FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst - Defense World
TSE:ONC FY2025 EPS Estimate Lifted by Leede Financial - Defense World
HC Wainwright Has Bearish Forecast for ONCY FY2029 Earnings - Defense World
HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech - Defense World
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference - GuruFocus.com
Biotech Advancing Pivotal Phase III Breast Cancer Trial - Streetwise Reports
Bridgewater Systems and Oncolytics Biotech Inc. Under Current Evaluation - ACCESS Newswire
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):